These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36625928)

  • 1. A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease.
    Yeo-Teh NSL; Tang BL
    Sci Eng Ethics; 2023 Jan; 29(1):2. PubMed ID: 36625928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease.
    Heidebrink JL; Paulson HL
    Annu Rev Med; 2024 Jan; 75():99-111. PubMed ID: 38285515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
    DiStefano MJ; Alexander GC; Polsky D; Anderson GF
    J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Making the Case for Accelerated Withdrawal of Aducanumab.
    Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
    J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Under-Represented Populations Left Out of Alzheimer's Disease Treatment with Aducanumab: Commentary on Ethics.
    Padala SP; Yarns BC
    J Alzheimers Dis Rep; 2022; 6(1):345-348. PubMed ID: 35891635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium Oligomannate: First Approval.
    Syed YY
    Drugs; 2020 Mar; 80(4):441-444. PubMed ID: 32020555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future.
    Esang M; Gupta M
    Cureus; 2021 Aug; 13(8):e17591. PubMed ID: 34646644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
    Xiao S; Chan P; Wang T; Hong Z; Wang S; Kuang W; He J; Pan X; Zhou Y; Ji Y; Wang L; Cheng Y; Peng Y; Ye Q; Wang X; Wu Y; Qu Q; Chen S; Li S; Chen W; Xu J; Peng D; Zhao Z; Li Y; Zhang J; Du Y; Chen W; Fan D; Yan Y; Liu X; Zhang W; Luo B; Wu W; Shen L; Liu C; Mao P; Wang Q; Zhao Q; Guo Q; Zhou Y; Li Y; Jiang L; Ren W; Ouyang Y; Wang Y; Liu S; Jia J; Zhang N; Liu Z; He R; Feng T; Lu W; Tang H; Gao P; Zhang Y; Chen L; Wang L; Yin Y; Xu Q; Xiao J; Cong L; Cheng X; Zhang H; Gao D; Xia M; Lian T; Peng G; Zhang X; Jiao B; Hu H; Chen X; Guan Y; Cui R; Huang Q; Xin X; Chen H; Ding Y; Zhang J; Feng T; Cantillon M; Chen K; Cummings JL; Ding J; Geng M; Zhang Z
    Alzheimers Res Ther; 2021 Mar; 13(1):62. PubMed ID: 33731209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Aducanumab for LMICs? Promises and Challenges.
    Gunawardena IPC; Retinasamy T; Shaikh MF
    Brain Sci; 2021 Nov; 11(11):. PubMed ID: 34827546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab.
    Chin E; Jaqua E; Safaeipour M; Ladue T
    Cureus; 2022 Nov; 14(11):e31065. PubMed ID: 36475205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases.
    Marsool MDM; Prajjwal P; Reddy YB; Marsool ADM; Lam JR; Nandwana V
    Dis Mon; 2023 May; 69(5):101547. PubMed ID: 36931947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Considerations in the Administration of Aducanumab for the Neurologist.
    Coerver K; Yu MM; D'Abreu A; Wasserman M; Nair KV
    Neurol Clin Pract; 2022 Apr; 12(2):169-175. PubMed ID: 35733944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
    Maulden A
    Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II randomized trial of sodium oligomannate in Alzheimer's dementia.
    Wang T; Kuang W; Chen W; Xu W; Zhang L; Li Y; Li H; Peng Y; Chen Y; Wang B; Xiao J; Li H; Yan C; Du Y; Tang M; He Z; Chen H; Li W; Lin H; Shi S; Bi J; Zhou H; Cheng Y; Gao X; Guan Y; Huang Q; Chen K; Xin X; Ding J; Geng M; Xiao S
    Alzheimers Res Ther; 2020 Sep; 12(1):110. PubMed ID: 32928279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Products from Plants and Algae for Treatment of Alzheimer's Disease: A Review.
    Klose J; Griehl C; Roßner S; Schilling S
    Biomolecules; 2022 May; 12(5):. PubMed ID: 35625622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.